Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292859 · ClinicalTrials.gov registry record
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
A clinical trial, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- 7
- Enrollment target
NCT05292859: Completed study, sponsored by Alaunos Therapeutics.
NCT05292859 is a clinical trial that has completed, run by Alaunos Therapeutics. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05292859 has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors
Primary Outcome
Incidence and duration of new related adverse events
Interventions
- BIOLOGICAL Neoantigen specific TCR-T cell drug product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2025-05-30 |
What the finished NCT05292859 record still lists
NCT05292859 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Neoantigen specific TCR-T cell drug product is the first listed.
NCT05292859 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05292859 about?
NCT05292859 is a clinical study titled "Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs". Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors
What is the current status of trial NCT05292859?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2023-03-01. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05292859?
The interventions under investigation include: Neoantigen specific TCR-T cell drug product (BIOLOGICAL).
Who is sponsoring clinical trial NCT05292859?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI